Stockscreener 앱 받기
0.9751
3.46%
-0.0349
시간 외 거래:
1.00
0.0249
+2.55%
전일 마감가:
$1.01
열려 있는:
$0.98
하루 거래량:
46,897
Relative Volume:
0.77
시가총액:
$71.79M
수익:
순이익/손실:
$-9.22M
주가수익비율:
-3.3428
EPS:
-0.2917
순현금흐름:
$-4.60M
1주 성능:
-7.13%
1개월 성능:
-20.07%
6개월 성능:
-29.34%
1년 성능:
-34.11%
1일 변동 폭
$0.96
$0.99
1주일 범위
$0.96
$1.0991
52주 변동 폭
$0.8885
$1.58
Telomir Pharmaceuticals Inc Stock (TELO) Company Profile
명칭
Telomir Pharmaceuticals Inc
전화
786-396-6723
주소
100 SE 2ND ST, MIAMI
Compare TELO vs VRTX, REGN, MRNA, ARGX, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
TELO
Telomir Pharmaceuticals Inc
|
0.9751 | 71.79M | 0 | -9.22M | -4.60M | -0.2917 |
VRTX
Vertex Pharmaceuticals Inc
|
523.93 | 132.80B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
805.02 | 82.88B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
200.10 | 79.89B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
873.71 | 54.94B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
377.63 | 42.72B | 5.76B | 514.49M | 1.10B | 4.4813 |
Telomir Pharmaceuticals Inc Stock (TELO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-02-21 | 개시 | Rodman & Renshaw | Buy |
Telomir Pharmaceuticals Inc 주식(TELO)의 최신 뉴스
Telomir raises $5.6M in common stock financing for cancer drug - Investing.com
Telomir Pharmaceuticals Raises $5.6 Million PIPE; Issues Placement Agent Warrants - TradingView
Telomir Pharmaceuticals Secures $5.6 Million Financing as - GlobeNewswire
Experimental drug found to slow bone cancer cell growth in dog and human lab tests - DVM360
Telomir announces preclinical study on AMD treatment candidate - Investing.com
Vision gains in fish study link Telomir (NASDAQ: TELO) eye data to its cancer program - Stock Titan
An experimental drug improved vision in an AMD model. Telomir’s focus is cancer. - Stock Titan
Telomir Announces Peer-Reviewed Publication Showing Telomir-Zn Restores Visual Function and Retinal Structure in a Model of Age-Related Macular Degeneration (AMD) - finance.yahoo.com
Telomir (TELO) investors approve all 2026 votes - Stock Titan
Form 8K Telomir Pharmaceuticals Inc For: 14 September By Investing.com - Investing.com Australia
Telomir Announces Research with The Ohio State University Demonstrating In-Vitro Anti-Cancer Activity in Human and Canine Osteosarcoma Models - finance.yahoo.com
Telomir Pharmaceuticals (TELO): John Paul DeJoria reports 5.169% ownership stake - Stock Titan
TELO Q4 2025 Earnings: Deep EPS Miss Underscores Pre-Revenue ChallengesFinancial Data - vinanet.vn
Telomir Flags Substantial Doubt About Ability to Continue as Going Concern - Minichart
TELO Q4 2025 Earnings: Deep EPS Miss Underscores Pre-Revenue ChallengesEarnings Miss Streak - careplusvn.com
Telomir Pharmaceuticals (NASDAQ:TELO) Releases Quarterly Earnings Results - MarketBeat
Telomir Pharmaceuticals | 10-Q: Q2 2026 Earnings Report - Moomoo
Telomir-Zn shows promise for iron-addicted cancers - BioWorld News
Telomir Pharmaceuticals (NASDAQ:TELO) Stock Price Down 3.4%Should You Sell? - MarketBeat
Telomir-Zn Preclinical Data Support Advancement in TNBC - TipRanks
Telomir Pharmaceuticals Announces Peer-Reviewed Publication of Preclinical Telomir-Zn Data Showing Tumor Suppression in Prostate and Triple-Negative Breast Cancer Models - Quiver Quantitative
Telomir Announces Peer-Reviewed Publication Demonstrating Telomir-Zn Suppresses Tumor Growth in TNBC and Prostate Cancer Models - Yahoo Finance
Telomir Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Officer Aminov Erez - Moomoo
Telomir Pharmaceuticals (TELO) Slides 3.4% to $1.21 as Key Support Level Comes into FocusFactor Rotation - vinanet.vn
Telomir Pharmaceuticals Inc. (TELO) Q4 2025 Earnings: Wider-than-Expected Loss Amid Pre-Revenue R&D Stage - dars.gov.et
Telomir Pharmaceuticals, Inc. Common Stock (NASDAQ: TELO) Stock Price, News & Analysis - Kalkine
Telomir Pharmaceuticals (TELO) grants 50,000 stock options to director - Stock Titan
Telomir Pharmaceuticals Inc (TELO) Valuation: PE, PB & Fair Value Analysis - TradingKey
TELO|Telomir Pharmaceuticals Inc|Price:1.230|Chg%:+0.080 - TradingKey
Telomir Pharmaceuticals (TELO) awards director 50,000 options at $1.34 exercise price - Stock Titan
Telomir Pharmaceuticals (TELO) awards director 50,000 stock options at $1.34 - Stock Titan
Telomir Pharmaceuticals Inc (TELO) Institutional Confidence - TradingKey
Telomir Pharmaceuticals Inc (TELO) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Telomir Pharmaceuticals Inc (TELO) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Telomir Pharmaceuticals Inc (TELO) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Telomir Pharmaceuticals Inc (TELO) Cash Flow - TradingKey
Telomir Pharmaceuticals Inc (TELO) Balance Sheet - TradingKey
Telomir Pharmaceuticals Inc (TELO) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Telomir Pharmaceuticals, Inc. Revenue Breakdown – NASDAQ:TELO - TradingView
Telomir Pharmaceuticals Inc (TELO) Income Statement - TradingKey
Telomir Pharmaceuticals Inc (TELO) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
12 Health Care Stocks Moving In Tuesday's Intraday Session - Sahm
Telomir Pharmaceuticals Inc. (TELO) Stock Price | Live Quotes & Charts | NASDAQ - timothysykes.com
TELO Q4 2025 Earnings: Wider-than-Expected Loss Amid Early-Stage Drug DevelopmentSaaS Earnings Trends - vinanet.vn
TELO Q4 2025 Earnings: Wider-than-Expected Loss but Stock Surges 17.5% Amid Strategic ProgressMargin Expansion Trends - vinanet.vn
Andriy Mushak Net Worth (2026) - GuruFocus
12 Health Care Stocks Moving In Friday's After-Market Session - benzinga.com
TELO Q4 2025 Earnings: EPS Misses Estimates by Wide Margin as Pre-Revenue Biotech Reports No RevenueEarnings Power Value - DonanımHaber
Number of shareholders of Telomir Pharmaceuticals, Inc. – NASDAQ:TELO - TradingView
Telomir Pharmaceuticals (TELO) Slips 2.3% as Stock Tests Key Support LevelThematic ETF Flow - dars.gov.et
Telomir Pharmaceuticals Inc (TELO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
3.09%
0.72%
자본화:
|
볼륨(24시간):